Access
To read this story in full you will need to login or make a payment (see right).
News Feature
Nature 404, 538-540 (6 April 2000) | doi:10.1038/35007253
Open Innovation Challenges
-
Novel Approaches to Protecting Maize from Insect Damage
The Seeker is looking for novel approaches to protecting maize from insect damage. This Challenge re...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
- More Challenges
- Powered by:
nature jobs
Two Post-Doctoral Position In Nanomedicine
- Fondazione IRCCS Istituto Neurologico "Carlo Besta" (FINCB)
- Via Celoria n.11, 20133 Milano, Italy
Faculty Positions
- University of Texas Medical Branch
- Galveston, TX United States
Whatever happened to leptin?
Marina Chicurel1
Abstract
Just five years ago, it seemed that a single protein might reverse the rising tide of obesity. What worked for mice has not yet translated to people. But watch this space, says Marina Chicurel.
By any reckoning, US$20 million is a lot to spend on a protein. But in May 1995, Amgen of Thousand Oaks, California, paid just that for the commercial rights to leptin, a hormone that made fat mice slim.
To read this story in full you will need to login or make a payment (see right).
